Bempedoic Acid
A prodrug that inhibits cholesterol synthesis specifically in the liver, leading to lower ApoB and LDL cholesterol without the side effects of statins, but it is currently expensive.
Common Themes
Videos Mentioning Bempedoic Acid
#129 - Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
Peter Attia MD
A recently introduced drug that inhibits cholesterol synthesis by targeting ATP citrate lyase, offering an additional ApoB-lowering option, especially for statin-intolerant patients.
Insights from Sam Harris, Dr. Peter Attia, Ramit Sethi, and Elizabeth Gilbert | The Tim Ferriss Show
Tim Ferriss
A drug used to lower cholesterol when statins are not tolerated or insufficient, particularly for hypersynthesizers.
Exercise, Nutrition, Hormones for Vitality & Longevity | Dr. Peter Attia
Andrew Huberman
A drug that blocks cholesterol synthesis specifically in the liver, offering a similar but less potent mechanism than statins with fewer side effects.
Dr. Peter Attia on Mastering Longevity – Insights on Cancer Prevention, Heart Disease, and Aging
FoundMyFitness
A prodrug that inhibits cholesterol synthesis specifically in the liver, leading to lower ApoB and LDL cholesterol without the side effects of statins, but it is currently expensive.
334 - Cardiovascular disease, the number one killer: development, biomarkers, apoB, and more
Peter Attia MD
255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia
Peter Attia MD
Another lipid-lowering drug with a good safety profile, comparable to newer agents.
2024 New Year’s Resolutions, AI Upheavel, & Much More! | The Random Show (4K)
Tim Ferriss
A newer component of Nexletol, combined with ezetimibe to manage lipid profiles.
Supplements for Longevity & Their Efficacy | Dr. Peter Attia
Andrew Huberman
A medication taken by Peter Attia to directly impact cardiovascular disease processes.
230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more
Peter Attia MD
An oral drug that blocks cholesterol synthesis (Upstream of HMG CoA reductase), lowering LDL by ~18% (monotherapy) or ~36% (with ezetimibe). It does not cause muscle symptoms or increase glucose, making it a good option for statin-intolerant patients.